[Stroke in atrial fibrillation patients already on oral anticoagulant: What more can be done?]

Emmanuel Touzé1, Doina Ciocanu1

  • 1Université Caen Basse Normandie, CHU Côte-de-Nacre, service de neurologie et unité neurovasculaire, 14000 Caen, France.

Presse Medicale (Paris, France : 1983)
|June 1, 2014
PubMed

Insights

Despite oral anticoagulants, 1-3% of atrial fibrillation patients experience ischemic stroke annually. Management strategies exist but lack specific study evaluation for these challenging cases.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Context:

  • Atrial fibrillation (AF) patients on oral anticoagulants (OACs) still face ischemic stroke risks.
  • Annual incidence of ischemic stroke in OAC-treated AF patients is 1-3%.
  • Potential causes include OAC efficacy fluctuations, non-cardioembolic stroke, or inadequate anticoagulation.

Purpose:

  • To review therapeutic options for ischemic stroke in AF patients despite OAC therapy.
  • To highlight the lack of specific clinical evaluations for these management strategies.

Summary:

  • Ischemic strokes in OAC-treated AF patients can stem from various mechanisms.
  • Current therapeutic approaches include enhanced patient education, switching anticoagulants, adding aspirin, or percutaneous left-appendage closure.
  • These interventions require further rigorous study to establish optimal use.

Impact:

  • Informs clinical decision-making for managing complex stroke cases in AF.
  • Identifies critical gaps in evidence for stroke prevention strategies in atrial fibrillation.
  • Guides future research priorities for improving anticoagulation efficacy and stroke risk reduction.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
889